MedDataX Logo

Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)

NCT ID: NCT01390805

Last Updated: 2017-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

462 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-11-30

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to collect and assess information on proper use of valaciclovir regarding safety and efficacy of long-term use in suppressive therapy for subjects with recurrent genital herpes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)

NCT01390857

Varicella
COMPLETED

A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons

NCT00079911

Herpes Genitalis
TERMINATED PHASE4

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

NCT00306293

Herpes Labialis
COMPLETED PHASE4

A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients

NCT00005663

Herpes Simplex HIV Infections Herpes Genitalis
UNKNOWN PHASE3

A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster

NCT02152800

Herpes Zoster
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genital Herpes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects with recurrent genital herpes

Valaciclovir Hydrochloride.

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Valaciclovir Hydrochloride.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who started suppressive therapy for recurrent genital herpes for the first time

Exclusion Criteria

* Subjects with a history of hypersensitivity to the ingredients of VALTREX or aciclovir
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

112319

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
NCT00158860 COMPLETED PHASE4
The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected Patients
NCT00002404 COMPLETED NA
A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
NCT00002000 COMPLETED NA
A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
NCT00002084 COMPLETED NA
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
NCT01346475 COMPLETED PHASE4
Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
NCT00527618 COMPLETED PHASE4
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
NCT00116844 COMPLETED PHASE4
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
NCT00362297 COMPLETED PHASE4
An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons
NCT01059084 WITHDRAWN NA
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
NCT00306787 COMPLETED PHASE3
Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding
NCT00803543 COMPLETED NA
Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir
NCT01689285 COMPLETED PHASE1
The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children
NCT00001054 WITHDRAWN PHASE1
Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers
NCT02226978 COMPLETED PHASE1
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
NCT00486200 COMPLETED PHASE2
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
NCT01658826 TERMINATED PHASE2
Fed Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg
NCT00650494 COMPLETED PHASE1
Valaciclovir to Prevent Transmission of Herpes Simplex Virus
NCT00001649 COMPLETED PHASE3
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
NCT00031486 COMPLETED PHASE3
Evaluation Of Valaciclovir In Patients With Chickenpox
NCT00169416 COMPLETED PHASE3
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
NCT01132729 COMPLETED NA
Palatability Testing of a New Paediatric Formulation of Valacyclovir
NCT01682109 COMPLETED PHASE4
A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
NCT02412917 TERMINATED PHASE3
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
NCT01453075 COMPLETED PHASE1
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
NCT00001038 COMPLETED PHASE3